Agilent Technologies expects the acquisition to improve its current software portfolio.
Agilent Technologies announced in a May 2, 2018 press release that it has entered into a definitive agreement to acquire Genohm, a Lausanne, Switzerland-based developer of highly differentiated, on-premise, and cloud-based software solutions for laboratory management.
The transaction is subject to closing conditions. Financial terms of the deal were not disclosed.
Genohm's main laboratory software automation suite, SLIMS, is a digital platform that provides laboratories with a rapidly deployable and seamless laboratory information management system (LIMS) and electronic lab notebook (ELN) environment that is used in biobanks, research labs, and next-generation sequencing facilities. The platform tracks data and samples, tests and users, and results and workflows from the original material shipment to the result from lab instruments and in-silico analysis pipelines. Genohm also has an application marketplace with preconfigured workflows to enable rapid system implementation across a broad range of industries and scientific workflows.
According to Agilent, this acquisition enhances Agilent's current software portfolio, adding LIMS and workflow management while expanding ELN capability. This combination will allow Agilent to bring greater context to analytical data, enabling scientists to generate results more efficiently.
"Genohm has an excellent footprint in the genomics space," said Kamni Vijay, PhD, vice president and general manager of Agilent's Genomics Division, in the press release. "This acquisition supports our strategy to offer complete next-generation sequencing workflows and improve the laboratory management of our genomic customers."
Source: Agilent
EXO Biologics and ExoXpert Reach Two Critical Milestones that Advance Exosomes
December 3rd 2024EXO Biologics and its subsidiary, ExoXpert, have received GMP certification of a European exosomes manufacturing facility and have successfully loaded mRNA and DNA payloads into GMP-grade exosomes for drug delivery.